Foghorn Therapeutics Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments
Foghorn Therapeutics Inc. (FHTX) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments of $188.00 thousand for the 12-month period ending 2020-12-31, per its 10-K/A filed 2022-08-09.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments · last filed 2022-08-09
- Foghorn Therapeutics Inc. adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for fiscal 2020 was $188.00K.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 12 month |
|---|---|
| 2020-12-31 | $188.00K 10-K/A · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |